Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Forge will help to advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications by providing cGMP manufacturing and development services for its novel AAV gene therapy platform.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Forge Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 08, 2023